Free Trial

Abbott Laboratories (ABT) 10K Form and Latest SEC Filings 2026

Abbott Laboratories logo
$87.89 -1.76 (-1.97%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$88.27 +0.38 (+0.43%)
As of 06/12/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Abbott Laboratories SEC Filings & Recent Activity

Abbott Laboratories (NYSE:ABT) has submitted 817+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Abbott Laboratories's financial statements. The most recent filing was a Form SD submitted on May 27, 2026.

Form 4
ABBOTT LABORATORIES Reports Ownership Change on Apr. 28, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Abbott Laboratories Files Current Report on Apr. 27, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Abbott Laboratories Files Quarterly Report on Apr. 29, 2026

The 10-Q contains Abbott Laboratories's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Abbott Laboratories SEC Filing History

Browse Abbott Laboratories' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/27/2026 3:47 PM
Abbott Laboratories (1800) Filer
Form SD
Specialized Disclosure Report  
05/15/2026 3:15 PM
Abbott Laboratories (1800) Subject
Alpern Robert J (1448074) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/29/2026 3:05 PM
Abbott Laboratories (1800) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/28/2026 7:07 PM
Abbott Laboratories (1800) Issuer
Conroy Kevin T (1306119) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 6:58 PM
Abbott Laboratories (1800) Issuer
Conroy Kevin T (1306119) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/28/2026 6:37 PM
Abbott Laboratories (1800) Issuer
STARKS DANIEL J (902132) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 6:45 PM
Abbott Laboratories (1800) Issuer
Stratton John G (1385262) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 6:14 PM
Abbott Laboratories (1800) Issuer
O'Grady Michael (1527742) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 6:21 PM
Abbott Laboratories (1800) Issuer
Roman Michael F (1577544) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 5:54 PM
Abbott Laboratories (1800) Issuer
McDew Darren W (1787479) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 6:02 PM
Abbott Laboratories (1800) Issuer
McKinstry Nancy (1294731) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 5:45 PM
Abbott Laboratories (1800) Issuer
Kumbier Michelle (1640036) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 5:27 PM
Abbott Laboratories (1800) Issuer
Gonzalez Patricia Paola (1879701) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 5:09 PM
Abbott Laboratories (1800) Issuer
Babineaux-Fontenot Claire (1736637) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 5:17 PM
Abbott Laboratories (1800) Issuer
Blount Sally E. (1537286) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 5:01 PM
Abbott Laboratories (1800) Issuer
Ahuja Nita (2102715) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/27/2026 5:34 PM
Abbott Laboratories (1800) Subject
Alpern Robert J (1448074) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 4:34 PM
Abbott Laboratories (1800) Issuer
Boudreau Philip P (1805099) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/27/2026 3:06 PM
Abbott Laboratories (1800) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/24/2026 3:06 PM
Abbott Laboratories (1800) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
04/17/2026 3:04 PM
Abbott Laboratories (1800) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/16/2026 6:36 AM
Abbott Laboratories (1800) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/02/2026 4:31 PM
Abbott Laboratories (1800) Issuer
Stratton John G (1385262) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2026 4:24 PM
Abbott Laboratories (1800) Issuer
Roman Michael F (1577544) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2026 4:15 PM
Abbott Laboratories (1800) Issuer
Gonzalez Patricia Paola (1879701) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2026 4:00 PM
Abbott Laboratories (1800) Issuer
Ahuja Nita (2102715) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2026 4:07 PM
Abbott Laboratories (1800) Issuer
Alpern Robert J (1448074) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/26/2026 2:05 PM
Abbott Laboratories (1800) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/25/2026 5:56 PM
Abbott Laboratories (1800) Issuer
ORVILLE JACOB A (1263312) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/25/2026 5:46 PM
Abbott Laboratories (1800) Issuer
ORVILLE JACOB A (1263312) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/23/2026 4:30 PM
Abbott Laboratories (1800) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/23/2026 7:54 AM
Abbott Laboratories (1800) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/13/2026 3:01 PM
Abbott Laboratories (1800) Filer
Form DEFA14A
03/13/2026 3:01 PM
Abbott Laboratories (1800) Filer
Form ARS
03/03/2026 7:10 PM
Abbott Laboratories (1800) Issuer
Salvadori Daniel Gesua Sive (1620564) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 7:15 PM
Abbott Laboratories (1800) Issuer
Scoggins Christopher J (1772286) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 7:20 PM
Abbott Laboratories (1800) Issuer
Shroff Eric (2058129) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 7:00 PM
Abbott Laboratories (1800) Issuer
Moreland Mary K (1783147) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 7:06 PM
Abbott Laboratories (1800) Issuer
Morrone Louis H. (1867666) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 6:44 PM
Abbott Laboratories (1800) Issuer
Earnhardt Lisa D (1530893) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 6:48 PM
Abbott Laboratories (1800) Issuer
Ford Robert B (1612571) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
Stranded On The Flood Plains of History (Ad)

The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.tc pixel

Read Porter's full briefing and get the ticker names today
03/03/2026 6:55 PM
Abbott Laboratories (1800) Issuer
MCCOY JOHN A. JR. (1644207) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 6:34 PM
Abbott Laboratories (1800) Issuer
Boudreau Philip P (1805099) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 6:39 PM
Abbott Laboratories (1800) Issuer
Cushman Elizabeth C. (2075371) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 7:36 PM
Abbott Laboratories (1800) Subject
Shroff Eric (2058129) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/02/2026 7:23 PM
Abbott Laboratories (1800) Subject
Salvadori Daniel Gesua Sive (1620564) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/02/2026 7:16 PM
Abbott Laboratories (1800) Subject
Morrone Louis H. (1867666) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/02/2026 6:59 PM
Abbott Laboratories (1800) Subject
MCCOY JOHN A. JR. (1644207) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/02/2026 7:05 PM
Abbott Laboratories (1800) Subject
Moreland Mary K (1783147) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/02/2026 6:53 PM
Abbott Laboratories (1800) Subject
Cushman Elizabeth C. (2075371) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/26/2026 6:02 PM
Abbott Laboratories (1800) Issuer
Salvadori Daniel Gesua Sive (1620564) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2026 6:15 PM
Abbott Laboratories (1800) Issuer
Scoggins Christopher J (1772286) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2026 6:24 PM
Abbott Laboratories (1800) Issuer
Shroff Eric (2058129) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2026 5:11 PM
Abbott Laboratories (1800) Issuer
Earnhardt Lisa D (1530893) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2026 5:21 PM
Abbott Laboratories (1800) Issuer
Ford Robert B (1612571) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2026 5:35 PM
Abbott Laboratories (1800) Issuer
MCCOY JOHN A. JR. (1644207) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2026 5:43 PM
Abbott Laboratories (1800) Issuer
Moreland Mary K (1783147) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2026 5:52 PM
Abbott Laboratories (1800) Issuer
Morrone Louis H. (1867666) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2026 4:46 PM
Abbott Laboratories (1800) Issuer
Boudreau Philip P (1805099) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/25/2026 6:01 AM
Abbott Laboratories (1800) Filer
Form 424B5
02/23/2026 8:31 AM
Abbott Laboratories (1800) Filer
Form 424B3
02/23/2026 7:55 AM
Abbott Laboratories (1800) Filer
Form S-3ASR
02/20/2026 3:17 PM
Abbott Laboratories (1800) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/06/2026 7:04 AM
Abbott Laboratories (1800) Issuer
STARKS DANIEL J (902132) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/26/2026 7:02 AM
Abbott Laboratories (1800) Issuer
Ford Robert B (1612571) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/22/2026 6:35 AM
Abbott Laboratories (1800) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/05/2026 5:46 PM
Abbott Laboratories (1800) Issuer
Stratton John G (1385262) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 5:26 PM
Abbott Laboratories (1800) Issuer
Roman Michael F (1577544) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 5:00 PM
Abbott Laboratories (1800) Issuer
Alpern Robert J (1448074) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 5:15 PM
Abbott Laboratories (1800) Issuer
Gonzalez Patricia Paola (1879701) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 6:31 PM
Abbott Laboratories (1800) Issuer
Ahuja Nita (2102715) Reporting
Form 3
Initial statement of beneficial ownership of securities  
12/19/2025 3:39 PM
Abbott Laboratories (1800) Issuer
Scoggins Christopher J (1772286) Reporting
Form 3
Initial statement of beneficial ownership of securities  
12/12/2025 4:04 PM
Abbott Laboratories (1800) Issuer
Salvadori Daniel Gesua Sive (1620564) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/03/2025 10:02 AM
Abbott Laboratories (1800) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
11/25/2025 3:17 PM
Abbott Laboratories (1800) Issuer
Shroff Eric (2058129) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/21/2025 3:06 PM
Abbott Laboratories (1800) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/20/2025 6:37 AM
Abbott Laboratories (1800) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/29/2025 3:22 PM
Abbott Laboratories (1800) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/15/2025 6:33 AM
Abbott Laboratories (1800) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/02/2025 3:50 PM
Abbott Laboratories (1800) Issuer
Roman Michael F (1577544) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/02/2025 3:34 PM
Abbott Laboratories (1800) Issuer
Alpern Robert J (1448074) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2025 4:39 PM
Abbott Laboratories (1800) Issuer
MCCOY JOHN A. JR. (1644207) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2025 4:31 PM
Abbott Laboratories (1800) Issuer
Boudreau Philip P (1805099) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/11/2025 4:53 PM
Abbott Laboratories (1800) Issuer
Boudreau Philip P (1805099) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/08/2025 5:30 PM
Abbott Laboratories (1800) Subject
Boudreau Philip P (1805099) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/17/2025 6:34 AM
Abbott Laboratories (1800) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/01/2025 4:32 PM
Abbott Laboratories (1800) Issuer
Stratton John G (1385262) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2025 4:13 PM
Abbott Laboratories (1800) Issuer
Gonzalez Patricia Paola (1879701) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2025 4:24 PM
Abbott Laboratories (1800) Issuer
Roman Michael F (1577544) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2025 3:40 PM
Abbott Laboratories (1800) Issuer
Cushman Elizabeth C. (2075371) Reporting
Form 3
Initial statement of beneficial ownership of securities  
07/01/2025 3:47 PM
Abbott Laboratories (1800) Issuer
Cushman Elizabeth C. (2075371) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
Is SpaceX really worth 1.78 Trillion? (Ad)

With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analyst Lance Ippolito says the real opportunity is elsewhere. He's identified 5 dirt-cheap stocks at the forefront of this mega-IPO, including a space ticker that Goldman Sachs, BlackRock, and Morgan Stanley are all buying, a rare resource miner Elon's entire empire depends on, and the chip supplier Starlink satellites can't function without. Access his free SpaceX Investing Blackbook before IPO day arrives.tc pixel

Get the free SpaceX Investing Blackbook and see all 5 names
(Data available from 1/1/2016 forward)

Abbott Laboratories SEC Filings - Frequently Asked Questions

Abbott Laboratories (ABT) has submitted 817+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Abbott Laboratories's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Abbott Laboratories's financial statements page.

The most recent filing was a Form SD submitted on May 27, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NYSE:ABT) was last updated on 6/14/2026 by MarketBeat.com Staff.
From Our Partners